Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01376310 · ClinicalTrials.gov registry record · Phase 2
GSK1120212 Rollover Study
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 159
- Enrollment target
NCT01376310 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 159 participants.
The verdict
NCT01376310, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 159 participants
- Enrollment target
Study Summary
This was an open-label study to permit subjects with solid tumors or leukemia, who were clinically benefitting on another GSK sponsored trial with GSK1120212 either monotherapy or in combination continued access to GSK1120212.
Interventions
- DRUG GSK1120212
- DRUG Docetaxel + GSK1120212
- DRUG Erlotinib + GSK1120212
- DRUG Pemetrexed + GSK1120212
- DRUG Carboplatin + GSK1120212
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2010-11-02 |
| Est. Completion | 2018-01-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01376310
The ClinicalTrials.gov registry entry for NCT01376310 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which GSK1120212 is the first listed.
NCT01376310 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01376310 about?
NCT01376310 is a clinical study titled "GSK1120212 Rollover Study". This was an open-label study to permit subjects with solid tumors or leukemia, who were clinically benefitting on another GSK sponsored trial with GSK1120212 either monotherapy or in combination continued access to GSK1120212.
What is the current status of trial NCT01376310?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 159 participants. The study started on 2010-11-02. Estimated completion is 2018-01-18.
What interventions are being tested in trial NCT01376310?
The interventions under investigation include: GSK1120212 (DRUG), Docetaxel + GSK1120212 (DRUG), Erlotinib + GSK1120212 (DRUG), Pemetrexed + GSK1120212 (DRUG), Carboplatin + GSK1120212 (DRUG).
Who is sponsoring clinical trial NCT01376310?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.